Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ariad Deal Is “Global Acquisition” Not Limited to US Market: Takeda CEO
January 11, 2017
- Teva Takeda Recalls Ciprofloxacin Generic
January 11, 2017
- Janssen, Fukushima Medical Univ. to Engage in Joint Research for ADHD Biomarkers
January 11, 2017
- Pharma Leaders Urge Govt to Lend Ear to Industry Opinions for Pricing Revamp
January 10, 2017
- Otsuka Files Schizophrenia Med Brexpiprazole in Japan
January 10, 2017
- Takeda, US Biotech Strike Deal on Celiac Disease Treatment
January 10, 2017
- Opdivo Gastric Cancer Filing Casts Cloud on Keytruda’s Sakigake Status
January 10, 2017
- Takeda to Buy US Oncology Firm Ariad
January 10, 2017
- Eisai Expands Deal with Arena, Gets All Global Rights to Belviq
January 6, 2017
- Kyowa Kirin’s KRN23 Filed in Europe for X-Linked Hypophosphatemia
January 6, 2017
- SSP Now under Sanofi Group in Japan after BI Biz Swap
January 6, 2017
- ASKA Eyes 33% Rise in Women’s Health Sales by FY2020
January 5, 2017
- ASKA Ties Up with TesoRx on Oral Testosterone Therapy
January 5, 2017
- Takeda Makes Foray into Consumer Diagnostic Biz with Ovulation, Pregnancy Tests
December 28, 2016
- Opdivo Filed for Gastric Cancer in Japan: Ono
December 28, 2016
- AZ Returns Meropenem Rights in Southeast Asia, HK to Sumitomo Dainippon
December 27, 2016
- SBI, Kubota to Form JV for Ophthalmic Drugs, Devices
December 27, 2016
- Aspen Japan to Launch Imigran AG on Jan. 16
December 27, 2016
- 40 Billion Yen Sales for Oncology Business in FY2020 Achievable: Daiichi Sankyo
December 27, 2016
- Towa to Discontinue Marketing Cabergoline Generic due to Failure in Dissolution Testing
December 27, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…